查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1727075

诊断用AI:市场考察·竞争情形·市场预测 (2032年)

Artificial Intelligence (AI) in Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

诊断人工智慧市场按组件（硬体/软体、服务）、应用（传染病诊断、放射学、肿瘤学、心臟病学等）、技术（机器学习、自然语言处理等）和地区（北美、欧洲、亚太地区及世界其他地区）细分，预计到 2032 年将维持强劲的复合年增长率。这得益于传染病和慢性病的增多、数位健康和​​影像技术的日益普及以及全球主要参与者产品开发活动的增加。

2024 年诊断人工智慧市场规模为 16.232 亿美元，预计在 2025-2032 年预测期内，复合年增长率将达到 22.31%，到 2032 年将达到 80.8197 亿美元。

传染病和慢性病的盛行率上升正在推动早期精准诊断的需求日益增长，而人工智慧在提高检测准确性和支援更快的临床决策方面发挥关键作用。同时，数位健康和​​影像技术的日益普及为将人工智慧工具融入现有医疗工作流程奠定了坚实的基础，从而提高了营运效率和诊断准确性。此外，机器学习的进步和监管机构日益增强的支持力度，促使全球各大公司加强产品开发力度，从而广泛提供基于人工智慧的诊断解决方案。这些因素共同促成了更准确、更及时、更具可扩展性的医疗服务，预计将在2025-2032年的预测期内推动人工智慧诊断市场的显着成长。

诊断人工智慧：市场动态

根据世界卫生组织提供的数据，截至2023年，全球估计有3,990万人感染爱滋病毒（HIV），约有130万人新感染爱滋病毒。同年，预计约有1,080万人将罹患结核病（TB）。诊断人工智慧在结核病和爱滋病毒管理中发挥关键作用，能够实现早期发现和高效监测。在结核病领域，人工智慧可以分析胸部X光片和CT扫描影像以识别感染模式，从而减少对放射科医生的依赖，尤其是在医疗资源匮乏的地区。在爱滋病毒领域，人工智慧有助于追踪病情进展、预测治疗反应并检测合併感染。这简化了工作流程，减少了诊断延误，并使大规模筛检更容易实施。

此外，全球癌症发生率的上升也是推动诊断人工智慧市场成长的主要因素。癌症诊断涉及复杂的影像分析、病理资讯和基因组数据，使其成为人工智慧应用的理想领域。根据世界卫生组织2024年的数据，2022年全球报告了2,000万例新增癌症病例，其中肺癌是最常见的癌症类型，占总数的12.4%，共计250万例。人工智慧诊断工具能够侦测人眼透过CT扫描和X光片可能遗漏的细微异常。人工智慧演算法可以分析肺组织中的结节、肿块和不规则结构，从而实现快速、高精度的诊断。

此外，根据英国心臟基金会（2025年）的数据，全球约有6.4亿人患有心臟和循环系统疾病。准确及时地发现这些疾病至关重要，因为早期诊断可以改善预后并降低死亡率。人工智慧工具正越来越多地被整合到诊断过程中，透过分析CT、MRI和超音波心动图等医学影像，比传统方法更准确、更有效率地解读复杂数据。

数位健康和​​影像诊断技术的广泛应用也推动了诊断人工智慧市场的发展，因为它提高了医疗诊断的速度、准确性和可近性。人工智慧演算法可以有效分析来自CT、MRI和X光片等的复杂影像数据，有助于肿瘤、循环系统和呼吸系统等领域的早期发现。例如，2024年12月，GE医疗在RSNA 2024大会上发布了其Sonic DL AI MRI演算法，该演算法在脑部、脊椎、骨科和躯干成像领域实现了高达86%的加速，并提升了影像品质。

本报告调查了全球诊断AI市场，并提供了市场概况、法律和监管环境、市场影响因素分析、市场规模趋势和预测、各细分市场和地区的详细分析、竞争格局以及主要公司概况。

本报告提供全球诊断用AI的市场调查，彙整市场概要，法律制度，市场影响因素的分析，市场规模的转变·预测，各种区分·各地区的详细分析，竞争情形，主要企业简介等资讯。

目录

第1章 诊断用AI:报告简介

  • 调查范围
  • 市场区隔
  • 市场估计

第2章 诊断用AI:摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

第5章 诊断用AI:主要要素分析

  • 推动市场要素
    • 传染病和慢性病发生率不断上升
    • 数位健康和​​影像技术的采用率不断提高
    • 主要参与者的产品开发活动不断增加全球
  • 市场限制与课题
    • 资料隐私与安全
    • 资料品质与数量欠佳
  • 诊断人工智慧：机遇
    • 持续研发罕见疾病及未确诊疾病的人工智慧整合技术

第6章 诊断用AI:波特的五力分析

第7章 诊断用AI的评估

  • 各零件
    • 硬体设备/软体
    • 服务
  • 各用途
    • 感染疾病诊断
    • 放射线
    • 肿瘤
    • 心臟病
    • 其他
  • 各技术
    • 机器学习
    • 自然语言处理
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 全球其他地区

第8章 诊断用AI:企业及产品简介

  • Aidoc
  • Qure.ai
  • GE HealthCare
  • Siemens Healthineers
  • PathAI
  • Ibex
  • Owkin, Inc
  • Imagen Technologies
  • Aiforia
  • RADLogics
  • Terarecon, Inc.
  • Prenosis, Inc.
  • Ibex
  • Google LLC
  • GE HealthCare
  • DreaMed
  • Riverain Technologies
  • Terarecon, Inc.
  • Aiforia
  • RADLogics

第9章 KOL的见解

第10章 计划方法

第11章 关于DelveInsight

第12章 免责声明·联络方式

Product Code: DIMDCL0864

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/software, and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of infectious and chronic diseases, growing adoption of digital health & imaging technologies, increase in product development activities among the key market players across the globe.

The Artificial Intelligence (AI) in Diagnostics market was valued at USD 1,623.20 million in 2024, growing at a CAGR of 22.31% during the forecast period from 2025 to 2032 to reach USD 8,081.97 million by 2032. The rising prevalence of infectious and chronic diseases is driving the demand for early and accurate diagnosis, where AI plays a vital role by enhancing detection and supporting faster clinical decisions. Simultaneously, the growing adoption of digital health and imaging technologies provides a strong foundation for integrating AI tools into existing healthcare workflows, improving efficiency and accuracy. Additionally, increased product development activities by key players across the globe fueled by advancements in machine learning and growing regulatory support are expanding the availability of AI-powered diagnostic solutions. Together, these factors are expected to significantly boost the global market for Artificial Intelligence (AI) in Diagnostics by enabling more precise, timely, and scalable healthcare delivery during the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Diagnostics Market Dynamics:

According to the data provided by the World Health Organization, in 2023, globally, an estimated 39.9 million people were living with HIV and approximately 1.3 million population acquired HIV. Additionally, as per the same source, in 2023, approximately 10.8 million people fell ill with tuberculosis (TB). Artificial Intelligence (AI) in Diagnostics is boosting the management of TB and HIV by enabling early detection and efficient monitoring. In TB, AI analyzes chest X-rays and CT scans to identify infection patterns, reducing reliance on radiologists, especially in low-resource areas. For HIV, AI supports disease progression tracking, treatment prediction, and detection of co-infections. These capabilities streamline workflows, reduce diagnostic delays, and enhance large-scale screening efforts.

Moreover, the rising global incidence of cancer is a major factor driving the growth of Artificial Intelligence (AI) in Diagnostics market. Cancer diagnosis often involves complex imaging, pathology, and genomic data, making it an ideal application for artificial intelligence. According, to the data provided by the World Health Organization (2024), in 2022, globally, there were an estimated 20 million new cancer cases with lung cancer being the most commonly occurring cancer worldwide with 2.5 million new cases accounting for 12.4% of the total new cases. AI-powered diagnostic tools, particularly those using CT scans and X-rays, are capable of detecting subtle signs of lung cancer that might be missed by the human eye. AI algorithms analyze imaging data to identify nodules, masses, and irregularities in lung tissues, allowing for quicker and more accurate detection.

In addition, according to data provided by the British Heart Foundation (2025), globally, around 640 million people were living with heart and circulatory diseases across the world. These diseases require precise and timely detection, as early diagnosis can greatly improve outcomes and reduce mortality rates. AI tools are increasingly being integrated into the diagnostic workflow to analyze medical imaging (e.g., CT, MRI, echocardiograms) and interpret complex data with higher accuracy and efficiency than traditional methods thereby escalating the overall market of Artificial Intelligence (AI) in Diagnostics.

Furthermore, the growing adoption of digital health and imaging technologies is boosting the AI diagnostics market by improving the speed, accuracy, and accessibility of medical diagnoses. AI algorithms efficiently analyze complex imaging data from CT scans, MRIs, and X-rays, aiding early detection in fields like oncology, cardiology, and pulmonology. For instance, in December 2024, GE HealthCare's Sonic DL AI MRI algorithm, launched at the RSNA 2024 conference, accelerates scans by up to 86% while enhancing image resolution for brain, spine, orthopedic, and body imaging.

Together, the above-mentioned factors are expected to boost the overall market of Artificial Intelligence (AI) in Diagnostics.

Despite these promising growth factors, the Artificial Intelligence (AI) in Diagnostics market faces challenges such as data privacy & security. Additionally, AI algorithms require large, high-quality datasets to train effectively, and integrating with existing healthcare systems can be challenging which may hinder the future market of Artificial Intelligence (AI) in Diagnostics during the forecast period.

Artificial Intelligence (AI) in Diagnostics Market Segment Analysis:

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/software, and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the component segment of the Artificial Intelligence (AI) in Diagnostics market, the software category is projected to capture a significant revenue share in 2024. Software solutions are playing a pivotal role in boosting the overall market of Artificial Intelligence (AI) in Diagnostics by significantly enhancing the capabilities of diagnostic tools, improving accuracy, and streamlining clinical workflows.

These software systems integrate AI algorithms with various medical devices, such as imaging machines (CT scans, MRIs, X-rays), laboratory testing equipment, and patient monitoring systems, enabling real-time analysis and interpretation of complex data. AI-powered diagnostic software can process large volumes of data rapidly, identifying patterns and anomalies that human clinicians might miss. For instance, in imaging, AI software helps detect early signs of diseases such as cancer, cardiovascular conditions, and neurological disorders by analyzing medical images for subtle irregularities that may not be visible to the naked eye. In pathology, AI software assists in the classification and grading of tumors or detecting abnormalities in tissue samples, which aids in accurate diagnosis and treatment planning.

Moreover, software innovations are driving advancements in personalized medicine by analyzing patient data to predict disease progression, identify the most effective treatment plans, and monitor ongoing responses to treatment. This capability is particularly valuable in chronic disease management, such as in diabetes, heart disease, and oncology, where continuous monitoring is essential for adjusting treatments and preventing complications. The automation provided by AI software also helps reduce diagnostic errors, minimize human workload, and enhance the efficiency of healthcare professionals, allowing them to focus more on patient care rather than time-consuming manual tasks. Furthermore, the integration of AI diagnostic software with electronic health records (EHRs) enables seamless data sharing across different healthcare systems, improving collaboration among specialists and ensuring more coordinated care. The growing availability of cloud-based AI diagnostic software solutions further supports scalability, making advanced diagnostic tools more accessible to healthcare providers, especially in underserved or resource-limited regions. As more software solutions are developed and validated, the AI diagnostics market is experiencing rapid growth.

Additionally, the increase in product development activities such as product launches and product approvals are further escalating the overall market. For instance, in July 2024, Tempus received FDA 510(k) clearance for its ECG-AF algorithm, an AI-based tool designed to identify patients at increased risk of atrial fibrillation (AFib). ECG-AF is the first of a suite of next-generation diagnostics that Tempus has designed to identify patients at risk for a variety of cardiovascular conditions.

Given these factors, the software segment is expected to witness robust growth during the forecast period, thereby driving the overall expansion of Artificial Intelligence (AI) in Diagnostics market.

North America is expected to dominate the overall Artificial Intelligence (AI) in Diagnostics market:

North America is projected to account for the largest share of Artificial Intelligence (AI) in Diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, increased adoption of imagining technologies, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

According to the data provided by the International Agency for Research on Cancer, in 2022, the estimated number of new cases of brain cancer was 24,940 and the projections were estimated to increase 31,278 cases by 2045. AI technologies, particularly those used in medical imaging like MRI and CT scans, play a crucial role in identifying brain tumors, pinpointing their exact location, and assessing their size and characteristics with high precision. AI algorithms can analyze complex brain scans faster and with greater accuracy than traditional methods, detecting even subtle signs of tumors that might be missed by human radiologists thereby escalating the need for Artificial Intelligence (AI) in Diagnostics across the region.

According to the data provided by the Government of Canada, in 2022, there were, 13,953 cases of syphilis were reported in Canada, marking an 11% increase from 2021. AI-powered diagnostic systems, such as those integrating machine learning with laboratory testing and imaging, can improve the speed and accuracy of syphilis detection. AI algorithms can analyze large datasets of medical images (such as syphilis-related lesions in oral, genital, or anal regions) and blood tests (like serologic tests), identifying subtle patterns or abnormalities that may be difficult to detect manually.

Additionally, the region benefits from ongoing advancements in Artificial Intelligence (AI) in Diagnostics -related R&D, product launches, and regulatory approvals. Such developments further accelerate market expansion. For instance, in October 2024, Owkin introduced MSIntuit(R) CRC v2, a next-generation AI diagnostic tool to improve colorectal cancer (CRC) detection.

In summary, the combination of a high disease burden, innovative R&D landscape, advanced healthcare infrastructure, and favorable regulatory policies makes North America a leading market for AI in Diagnostic market throughout the forecast period.

Artificial Intelligence (AI) in Diagnostics Key Players:

Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

Recent Developmental Activities in the Artificial Intelligence (AI) in Diagnostics Market:

  • In September 2024, Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, introduced the latest advancements in its innovative product platform, Ibex-AI. These new features, developed in collaboration with expert pathologists worldwide who actively use the platform in routine clinical practice, highlight Ibex's ongoing commitment to creating cutting-edge diagnostic tools tailored to the needs of healthcare professionals on the frontlines of patient care.
  • In October 2023, Lucida Medical Ltd, announced that it received Class IIb CE certification for its AI-powered prostate cancer detection software, Prostate IntelligenceTM (PiTM) Leveraging advanced AI technology, PiTM analyzes MRI scans and is seamlessly integrated into the radiologist's workflow.
  • In March 2023, Qritive launched its latest AI-driven innovation QAi Prostate, designed specifically for prostate cancer diagnosis. Utilizing cutting-edge machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies with high precision.

Key Takeaways from the Artificial Intelligence (AI) in Diagnostics Market Report Study

  • Market size analysis for current Artificial Intelligence (AI) in Diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the Artificial Intelligence (AI) in Diagnostics market.
  • Various opportunities available for the other competitors in Artificial Intelligence (AI) in Diagnostics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Artificial Intelligence (AI) in Diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Artificial Intelligence (AI) in Diagnostics market growth in the coming future?

Target Audience Who Can be benefited from this Artificial Intelligence (AI) in Diagnostics Market Report Study

  • Artificial Intelligence (AI) in Diagnostics product providers
  • Research organizations and consulting companies
  • Artificial Intelligence (AI) in Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Artificial Intelligence (AI) in Diagnostics
  • Various end-users who want to know more about the Artificial Intelligence (AI) in Diagnostics market and the latest technological developments in the Artificial Intelligence (AI) in Diagnostics market.

Frequently Asked Questions for the Artificial Intelligence (AI) in Diagnostics Market:

1. What is Artificial Intelligence (AI) in Diagnostics?

  • Artificial Intelligence (AI) in Diagnostics refers to the use of artificial intelligence technologies, such as machine learning and deep learning algorithms, to analyze medical data (such as images, lab results, or patient records) to assist in diagnosing diseases and conditions. AI can enhance diagnostic accuracy, speed, and efficiency by detecting patterns or abnormalities that might be overlooked by human clinicians. It is widely used in areas like medical imaging, pathology, genomics, and disease monitoring, helping healthcare professionals make more informed decisions and improve patient outcomes.

2. What is the market for Artificial Intelligence (AI) in Diagnostics?

  • The Artificial Intelligence (AI) in Diagnostics market was valued at USD 1,623.20 million in 2024, growing at a CAGR of 22.31% during the forecast period from 2025 to 2032 to reach USD 8,081.97 million by 2032.

3. What are the drivers for the global Artificial Intelligence (AI) in Diagnostics market?

  • The rising prevalence of infectious and chronic diseases is driving the demand for early and accurate diagnosis, where AI plays a vital role by enhancing detection and supporting faster clinical decisions. Simultaneously, the growing adoption of digital health and imaging technologies provides a strong foundation for integrating AI tools into existing healthcare workflows, improving efficiency and accuracy. Additionally, increased product development activities by key players across the globe-fueled by advancements in machine learning and growing regulatory support-are expanding the availability of AI-powered diagnostic solutions. Together, these factors are expected to significantly boost the global market for Artificial Intelligence (AI) in Diagnostics by enabling more precise, timely, and scalable healthcare delivery during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Artificial Intelligence (AI) in Diagnostics market?

  • Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

5. Which region has the highest share in the global Artificial Intelligence (AI) in Diagnostics market?

  • North America is projected to account for the largest share of the Artificial Intelligence (AI) in Diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, increased adoption of imagining technologies, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

Table of Contents

1. Artificial Intelligence (AI) in Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Artificial Intelligence (AI) in Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

5. Artificial Intelligence (AI) in Diagnostics Market Key Factors Analysis

  • 5.1. Artificial Intelligence (AI) in Diagnostics Market Drivers
    • 5.1.1. Rising cases of infectious and chronic diseases
    • 5.1.2. Growing adoption of digital health & imaging technologies
    • 5.1.3. Increase in product development activities among the key market players across the globe
  • 5.2. Artificial Intelligence (AI) in Diagnostics Market Restraints and Challenges
    • 5.2.1. Data privacy and security
    • 5.2.2. Low data quality and quantity
  • 5.3. Artificial Intelligence (AI) in Diagnostics Market Opportunities
    • 5.3.1. Ongoing research and development in integrating AI for rare and undiagnosed diseases

6. Artificial Intelligence (AI) in Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Artificial Intelligence (AI) in Diagnostics Market Assessment

  • 7.1. By Component
    • 7.1.1. Hardware/Software
    • 7.1.2. Services
  • 7.2. By Application
    • 7.2.1. Infectious Disease Diagnostics
    • 7.2.2. Radiology
    • 7.2.3. Oncology
    • 7.2.4. Cardiology
    • 7.2.5. Others
  • 7.3. By Technology
    • 7.3.1. Machine Learning
    • 7.3.2. Natural Language Processing
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.3. India Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)

8. Artificial Intelligence (AI) in Diagnostics Market Company and Product Profiles

  • 8.1. Aidoc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Qure.ai
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. GE HealthCare
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Siemens Healthineers
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. PathAI
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Ibex
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Owkin, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Imagen Technologies
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Aiforia
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. RADLogics
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Terarecon, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Prenosis, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Ibex
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Google LLC
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. GE HealthCare
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. DreaMed
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Riverain Technologies
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Terarecon, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Aiforia
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. RADLogics
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Artificial Intelligence (AI) in Diagnostics Market in Global (2022-2032)
  • Table 3: Artificial Intelligence (AI) in Diagnostics Market in Global by Component (2022-2032)
  • Table 4: Artificial Intelligence (AI) in Diagnostics Market in Global by Application (2022-2032)
  • Table 5: Artificial Intelligence (AI) in Diagnostics Market in Global by Technology (2022-2032)
  • Table 6: Artificial Intelligence (AI) in Diagnostics Market in Global by Geography (2022-2032)
  • Table 7: Artificial Intelligence (AI) in Diagnostics Market in North America (2022-2032)
  • Table 8: Artificial Intelligence (AI) in Diagnostics Market in the United States (2022-2032)
  • Table 9: Artificial Intelligence (AI) in Diagnostics Market in Canada (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Diagnostics Market in Mexico (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Diagnostics Market in Europe (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Diagnostics Market in France (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Diagnostics Market in Germany (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Diagnostics Market in United Kingdom (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Diagnostics Market in Italy (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Diagnostics Market in Spain (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Diagnostics Market in China (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Diagnostics Market in Japan (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Diagnostics Market in India (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Diagnostics Market in Australia (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Diagnostics Market in South Korea (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Diagnostics Market in the Rest of the World (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Diagnostics Market in the Middle East (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Diagnostics Market in Africa (2022-2032)
  • Table 28: Artificial Intelligence (AI) in Diagnostics Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Artificial Intelligence (AI) in Diagnostics Market in Global (2022-2032)
  • Figure 3: Artificial Intelligence (AI) in Diagnostics Market in Global by Component (2022-2032)
  • Figure 4: Artificial Intelligence (AI) in Diagnostics Market in Global by Application (2022-2032)
  • Figure 5: Artificial Intelligence (AI) in Diagnostics Market in Global by Technology (2022-2032)
  • Figure 6: Artificial Intelligence (AI) in Diagnostics Market in Global by Geography (2022-2032)
  • Figure 7: Artificial Intelligence (AI) in Diagnostics Market in North America (2022-2032)
  • Figure 8: Artificial Intelligence (AI) in Diagnostics Market in the United States (2022-2032)
  • Figure 9: Artificial Intelligence (AI) in Diagnostics Market in Canada (2022-2032)
  • Figure 10: Artificial Intelligence (AI) in Diagnostics Market in Mexico (2022-2032)
  • Figure 11: Artificial Intelligence (AI) in Diagnostics Market in Europe (2022-2032)
  • Figure 12: Artificial Intelligence (AI) in Diagnostics Market in France (2022-2032)
  • Figure 13: Artificial Intelligence (AI) in Diagnostics Market in Germany (2022-2032)
  • Figure 14: Artificial Intelligence (AI) in Diagnostics Market in United Kingdom (2022-2032)
  • Figure 15: Artificial Intelligence (AI) in Diagnostics Market in Italy (2022-2032)
  • Figure 16: Artificial Intelligence (AI) in Diagnostics Market in Spain (2022-2032)
  • Figure 17: Artificial Intelligence (AI) in Diagnostics Market in the Rest of Europe (2022-2032)
  • Figure 18: Artificial Intelligence (AI) in Diagnostics Market in Asia-Pacific (2022-2032)
  • Figure 19: Artificial Intelligence (AI) in Diagnostics Market in China (2022-2032)
  • Figure 20: Artificial Intelligence (AI) in Diagnostics Market in Japan (2022-2032)
  • Figure 21: Artificial Intelligence (AI) in Diagnostics Market in India (2022-2032)
  • Figure 22: Artificial Intelligence (AI) in Diagnostics Market in Australia (2022-2032)
  • Figure 23: Artificial Intelligence (AI) in Diagnostics Market in South Korea (2022-2032)
  • Figure 24: Artificial Intelligence (AI) in Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Artificial Intelligence (AI) in Diagnostics Market in the Rest of the World (2022-2032)
  • Figure 26: Artificial Intelligence (AI) in Diagnostics Market in the Middle East (2022-2032)
  • Figure 27: Artificial Intelligence (AI) in Diagnostics Market in Africa (2022-2032)
  • Figure 28: Artificial Intelligence (AI) in Diagnostics Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Marker Opportunities
  • Figure 32: PORTER'S Five Force Analysis